EUVIMEDEUVIMED entdecken
Open Access

Buprenorphine Dose and Time to Discontinuation Among Patients With Opioid Use Disorder in the Era of Fentanyl

Laura C Chambers, Benjamin D Hallowell, Andrew R Zullo, Taylor J Paiva, Justin Berk, Rachel Gaither, Aidan J Hampson, Francesca L Beaudoin, Rachel S Wightman

JAMA Network Open · 18.09.2023 · 6 (9) · e2334540

DOI: 10.1001/jamanetworkopen.2023.34540 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 18.09.2023. Verfasst von Laura C Chambers und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Brown University, Providence, Rhode Island. Hauptthemen laut MEDLINE: Buprenorphine, Opioid-Related Disorders. Die Arbeit wurde bisher 117-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, NIMH NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Buprenorphine treatment for opioid use disorder (OUD) has more than doubled since 2009. However, current US Food and Drug Administration buprenorphine dosing guidelines are based on studies among people using heroin, prior to the emergence of fentanyl in the illicit drug supply.

Objective

To estimate the association between buprenorphine dose and time to treatment discontinuation during a period of widespread fentanyl availability. Design, Setting, and Participants This retrospective cohort study used statewide Rhode Island Prescription Drug Monitoring Program data. Participants were Rhode Island residents initiating buprenorphine treatment for OUD between October 1, 2016, and September 30, 2020. Data analysis was performed from December 9, 2022, to August 10, 2023. Exposure Daily dose of buprenorphine (16 mg and 24 mg) defined starting on the day of initiation based on total quantity and days’ supply dispensed. Patients were censored on any dose change. Main Outcomes and Measures Buprenorphine treatment discontinuation in the 180 days following initiation, defined as a gap in treatment of more than 27 days based on prescription fill dates and days’ supply. Kaplan-Meier and Cox regression survival analyses were conducted to estimate the association between buprenorphine dose and time to treatment discontinuation, controlling for potential informative censoring and measured potential confounders.

Results

Among 6499 patients initiating buprenorphine treatment for OUD, most were aged 25 to 44 years (57%; n = 3682), were male (61%; n = 3950), and had private (47%; n = 3025) or Medicaid (33%; n = 2153) insurance. More than half of patients were prescribed a daily dose of interest at initiation (16 mg: 50%; n = 3264; 24 mg: 10%; n = 668). In Kaplan-Meier analyses, 58% of patients discontinued buprenorphine treatment within 180 days (16 mg: 59% vs 24 mg: 53%; log-rank test P = .005). In Cox regression analyses, patients prescribed a dose of 16 mg had a greater risk of treatment discontinuation than those prescribed 24 mg (adjusted hazard ratio, 1.20; 95% CI, 1.06-1.37). Conclusions and Relevance In this cohort study of patients initiating buprenorphine treatment from 2016 to 2020, patients prescribed a 24 mg dose of buprenorphine remained in treatment longer than those prescribed 16 mg. The value of higher buprenorphine doses than currently recommended needs to be considered for improving retention in treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BuprenorphineOpioid-Related DisordersUnited StatesHumansMaleFemaleCohort StudiesRetrospective StudiesFentanyl

Substanzen

BuprenorphineFentanyl

Autor:innen und Institutionen

  • Department of Epidemiology, Brown University, Providence, Rhode Island.
  • Substance Use Epidemiology Program, Rhode Island Department of Health, Providence.
  • Department of Medicine, Alpert Medical School of Brown University, Providence, Rhode Island.
  • Division of Therapeutics and Medical Consequences, National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland.
  • Department of Emergency Medicine, Alpert Medical School of Brown University, Providence, Rhode Island.

Förderung

  • NIDA NIH HHS
  • NIMH NIH HHS

Zitieren

APA

Chambers, L. C., Hallowell, B. D., Zullo, A. R., Paiva, T. J., Berk, J., Gaither, R., Hampson, A. J., Beaudoin, F. L., & Wightman, R. S. (2023). Buprenorphine Dose and Time to Discontinuation Among Patients With Opioid Use Disorder in the Era of Fentanyl. JAMA Network Open, 6(9), e2334540. https://doi.org/10.1001/jamanetworkopen.2023.34540

Vancouver

Chambers LC, Hallowell BD, Zullo AR, Paiva TJ, Berk J, Gaither R, et al. Buprenorphine Dose and Time to Discontinuation Among Patients With Opioid Use Disorder in the Era of Fentanyl. JAMA Network Open. 2023;6(9):e2334540. doi:10.1001/jamanetworkopen.2023.34540

BibTeX
@article{Chambers2023,
  author = {Chambers, Laura C and Hallowell, Benjamin D and Zullo, Andrew R and Paiva, Taylor J and Berk, Justin and Gaither, Rachel and Hampson, Aidan J and Beaudoin, Francesca L and Wightman, Rachel S},
  title = {Buprenorphine Dose and Time to Discontinuation Among Patients With Opioid Use Disorder in the Era of Fentanyl},
  journal = {JAMA Network Open},
  year = {2023},
  volume = {6},
  number = {9},
  pages = {e2334540},
  doi = {10.1001/jamanetworkopen.2023.34540}
}
Kostenlos starten →